drugset / Trial / NCT05667298
Organ-Preserving Endoscopic Resection & Adjuvant RADIO-immuno-chemotherapy for Esophageal Cancer
Phase 1
Active not recruiting
11 enrolled
University of Manitoba
AstraZeneca · collabCancerCare Manitoba · collabManitoba Medical Service Foundation · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The goal of this study is to assess the safety of delivering concurrent adjuvant chemoradiation or immuno-radiation therapy after EMR/ESD in pT1b/T2N0 esophageal cancer patients. The main objectives of the study are: 1. Assess the feasibility of enrolling 10 patients. 2. Assess the safety of delivering concurrent adjuvant chemoradiation or immunoradiation therapy after EMR/ESD in pT1b/T2 esophageal cancer patients
Timeline
- Start
- 2023-03-01
- Primary completion
- 2025-06-20
- Completion
- 2029-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | — | — |